Loading…

Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity

Recombinant erythropoietin (EPO) has been marketed as biopharmaceutical for anemia and chronic renal failure. Long-acting EPO variants that aimed at achieving less frequent dosing have been generated, either by the addition of glycosylation sites or increasing its molecular weight. The hEPO cDNA lin...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta 2015-09, Vol.1850 (9), p.1685-1693
Main Authors: Salgado, Emilio R., Montesino, Raquel, Jiménez, Sivana P., González, Mauricio, Hugues, Florence, Cabezas, Oscar I., Maura-Perez, Rafael, Saavedra, Paulina, Lamazares, Emilio, Salas-Burgos, Alexis, Vera, Juan C., Sánchez, Oliberto, Toledo, Jorge R.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recombinant erythropoietin (EPO) has been marketed as biopharmaceutical for anemia and chronic renal failure. Long-acting EPO variants that aimed at achieving less frequent dosing have been generated, either by the addition of glycosylation sites or increasing its molecular weight. The hEPO cDNA linked to the human IgG Fc fragment was cloned as a single codifying gene on the pAdtrack-CMV vector, yielding the recombinant adenoviral genome. For in vitro and in vivo expression assays cervical cancer cell line (SiHa) and nulliparous goats were used, respectively. The hematopoietic activity of EPO-Fc, expressed as the differential increment of hematocrit was evaluated in B6D2F1 mice. NP-HPLC of the 2AB-labeled N-glycan was carried out to profile analysis. The direct transduction of mammary secretory cells with adenoviral vector is a robust methodology to obtain high levels of EPO of up to 3.5mg/mL in goat's milk. SiHa-derived EPO-Fc showed significant improvement in hematopoietic activity compared to the commercial hEPO counterpart or with the homologous milk-derived EPO-Fc. The role of the molecular weight seemed to be important in enhancing the hematopoietic activity of SiHa-derived EPO-Fc. However, the lack of sialylated multi-antennary glycosylation profile in milk-derived EPO-Fc resulted in lower biological activity. The low content of tri- or tetra-antennary sialylated N-glycans linked to the chimeric EPO-Fc hormone, expressed in the goat mammary gland epithelial cells, defined its in vivo hematopoietic activity. The sialylated N-glycan content plays a more significant role in the in vivo biological activity of hEPO than its increased molecular weight. [Display omitted] •Mammary gland adenoviral transduction is a robust methodology for protein expression.•A sialylated N-glycans profile defines the hematopoietic activity of EPO-Fc variants.•Goat mammary cells aren't a proper system for the active glyco-hormones expression.
ISSN:0304-4165
0006-3002
1872-8006
DOI:10.1016/j.bbagen.2015.04.012